Study of CART-ddBMCA in Relapsed or Refractory Multiple Myeloma (iMMagine-1)
Summary
Third Opinion Trial Synopsis:
This study is testing a new treatment called CART-ddBCMA for people who have multiple myeloma and it has come back after treatment or is not responding to treatment. CART-ddBCMA is a type of therapy that uses special cells to fight the cancer.
This study is testing a new treatment called CART-ddBCMA for people who have multiple myeloma and it has come back after treatment or is not responding to treatment. CART-ddBCMA is a type of therapy that uses special cells to fight the cancer.
*Third Opinion AI Generated Synopsis
Trial Summary
A Phase II study of CART-ddBCMA for patients with relapsed or refractory multiple myeloma. CART-ddBCMA is a BCMA-directed CAR-T cell therapy
A Phase II study of CART-ddBCMA for patients with relapsed or refractory multiple myeloma. CART-ddBCMA is a BCMA-directed CAR-T cell therapy
Locations & Contact
Fill out the form and "Notify Multiple Myeloma Research Foundation" to let the Multiple Myeloma Research Foundation know you are interested in this trial.
Contacts: